Navigation Links
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Date:4/3/2011

a composite of death, myocardial infarction (MI), urgent target vessel revascularization (TVR) or recurrent ischemia at 30 days.  

Previously presented data from RADAR (AHA, November 2010) confirmed that pegnivacogin dosed at 1mg/kg reproducibly resulted in near complete inhibition of FIXa in an ACS population.  The latest RADAR results showed that ACUITY major bleeding following immediate sheath removal exhibited a dose response with bleeding rates decreasing with increasing levels of reversal.  Rates of bleeding were lower in the 75% and 100% reversal arms than heparin.  In addition, the incidence of ischemic events was lower in REG1 treated patients compared with those treated with heparin.  

Adverse events (AEs) other than bleeding and ischemic events were rare and evenly distributed among the arms of the study.  Three patients, clustered late in the trial and in Europe, had allergic-like reactions shortly after receiving pegnivacogin.  Characterization of these reactions is ongoing.  

"We are thrilled by the results of RADAR and the groundbreaking advance in anticoagulant therapy that they foretell.  It is now clear that control matters.  REG1 uniquely has shown the promise of simultaneously reducing ischemia and bleeding in comparison to heparin," said Dr. David J. Mazzo, President and CEO of Regado Biosciences, Inc.  He added, "The results of the RADAR trial solidly support Phase 3 development of REG1 in the broader ACS population.  Regado plans to move forward in this indication as well as in a parallel indication of open heart surgery."  

"The Phase 2b RADAR results suggest that high intensity FIXa inhibition with active control may ultimately represent a potential treatment option for addressing both ischemic and bleeding endpoints for patients who require short term anticoagulation in acute care settings," said John H. Alexander, MD, MHS, FACC of the Duke Clinica
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
2. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
3. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
4. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
8. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
9. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
10. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
11. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Landauer, Inc. (NYSE: ... environmental radiation measurement and monitoring, outsourced medical physics services ... will release financial results for the fiscal third quarter ... 2015. The Company will also host ... 2015 at 9:00 a.m. Central Time (10:00 a.m. Eastern ...
(Date:8/3/2015)... Calif., Aug. 3, 2015 AcelRx Pharmaceuticals, Inc. ... on the development and commercialization of innovative therapies for ... update and reported financial results for the three and ... highlights include: , On July 23, 2015, the ... a positive opinion for Zalviso™ for the management of ...
(Date:8/3/2015)... 3, 2015  LEO Pharma supports the recent decision ... include psoriasis as one of eight priority disease areas ... .  Psoriasis is an autoimmune disease that has a ... 7.5 million people in the US alone. ii ... to supporting patients living with psoriasis, LEO Pharma along ...
Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3
... India, Oct. 19 Cardiac Science Corporation (Nasdaq: ... NSE: OPTOCIRCUI] today announced they have entered into a definitive ... all of the outstanding shares of Cardiac Science common stock ... 10% premium to the closing price of Cardiac Science common ...
... 18 Althea Technologies, Inc., a leading provider ... parenteral drug products, announced today that it has ... high-speed syringe filling line.  This line is located ... in San Diego. The expanded capacity complements existing ...
Cached Medicine Technology:Opto Circuits to Acquire Cardiac Science 2Opto Circuits to Acquire Cardiac Science 3Opto Circuits to Acquire Cardiac Science 4Opto Circuits to Acquire Cardiac Science 5Opto Circuits to Acquire Cardiac Science 6Opto Circuits to Acquire Cardiac Science 7Althea Technologies Announces the Installation of a High-Speed Prefilled Syringe Line 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... contract research organisations (CROs) for a slew of benefits, allowing them to gain ... operations, boost quality with cost-effective utilisation of resources, get access to innovation and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los Angeles ... need. Most people know that general health emergencies, such as broken arms or a ... people know where to turn to during a dental emergency. This is important, because ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... A July ... Injection of Stem Cells Found to Release Natural Painkiller That Can Last 'For Five ... patients. According to the report, the new study showed that harvesting stem cell-rich bone ...
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from Romania wanted to ... by diabetes after many years of suffering and using medications with strong side effects. ... to ask for extra time off or wait longer hours in the waiting rooms. ...
Breaking Medicine News(10 mins):Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3
... Introduces New Educational ... Resource at IDSA Annual Meeting, HADDON HEIGHTS, ... a new continuing education,resource as part of their exhibit booth ... America (IDSA), October 4-7, in San Diego,California. Project CDAD: Outbreak ...
... reveal new ways of controlling and treating breast cancer ... today (Monday 1 October 2007). , Dr Robert Clarke ... group have been investigating human breast cancers for the ... tumours and can cause the cancer to recur - ...
... CHICAGO, Oct. 1 Y-ME Illinois will host a ... and,friends. The BIG Night Out - Indulgence for ... 6:30 p.m. to 10:00 p.m. in the Great Hall ... pamper themselves by,partaking in indulgences such as onsite spa ...
... Oct. 1 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,Corp. today ... signed amended,agreements with Smith & Nephew wound ... dressings with SILCRYST(TM) nanocrystalline coatings.,The two companies ... when Smith &,Nephew bought the Acticoat(TM) brand ...
... WINDSOR, Conn., Oct. 1 UTC Power, a,United ... announced it has,acquired Dome- Tech Group, a national ... New York City. Financial terms were not disclosed. ... energy costs,and improve overall efficiency. It facilitates green, ...
... Achieve Optimum Health, SOMERSET, N.J., Oct. 1 ... announced that it has launched a fourth business,segment, ... pharmaceutical,companies and healthcare payors achieve the best possible ... and stay on the right therapy, everyone wins ...
Cached Medicine News:Health News:National Experts Team Up to Help Hospitals Prevent and Control C. difficile Outbreaks 2Health News:Manchester researchers announce new methods of beating breast cancer 2Health News:Y-ME Illinois Hosts the First-Ever 'BIG Night Out' - Indulgence for a Cause 2Health News:NUCRYST and Smith & Nephew Revise Agreements 2Health News:NUCRYST and Smith & Nephew Revise Agreements 3Health News:NUCRYST and Smith & Nephew Revise Agreements 4Health News:NUCRYST and Smith & Nephew Revise Agreements 5Health News:NUCRYST and Smith & Nephew Revise Agreements 6Health News:NUCRYST and Smith & Nephew Revise Agreements 7Health News:UTC Power Acquires Dome-Tech Group 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 3
... a powerful, compact and programmable 8-channel ... dispensing pumps. Dispense and aspirate head ... horizontal needle positioning in the well. ... waste bottles and vacuum sensing allow ...
... is a solid made, manual plate ... valves for dispense and aspirate function ... complete with a stand and all ... be used, as well as any ...
... of microplate washers are precise, fast and ... manifold, providing independent control of both dispense ... and overflow protection in both 96- and ... the most precise and reliable washer available ...
... The Microplate washer MP-1200 is ... microplate washing system. Its internal micropumps ... and to discharge from all types ... microplate to be washed in rows ...
Medicine Products: